<DOC>
	<DOCNO>NCT00835159</DOCNO>
	<brief_summary>The purpose study determine whether preoperative administration Rivastigmine prevent incidence postoperative delirium patient undergo major surgery well postoperative cognitive dysfunction .</brief_summary>
	<brief_title>Rivastigmine Treatment Postoperative Delirium : Pilot Clinical Trial</brief_title>
	<detailed_description>Postoperative delirium ( POD ) Postoperative cognitive dysfunction ( POCD ) common significant postoperative complication elderly patient . A reduction postoperative complication would lead improved functional status , great independence reduction health care cost . Scientific evidence show acetylcholinesterase inhibitor may reduce incidence and/or severity postoperative delirium . We propose conduct randomize , double-masked , placebo-controlled study ass effectiveness Rivastigmine , acetylcholinesterase inhibitor . Rivastigmine transdermal system ( Exelon Patch ) approve FDA treatment mild moderate Alzheimer 's dementia mild moderate dementia associate Parkinson 's disease . Patients 65 y.o . old undergo major elective surgery qualify study base risk assessment guideline . Patients screen include Mini Mental Status Examination ( MMSE assess baseline cognitive function ) , Hamilton scale ( screen depression ) , Telephone Interview Cognitive Status Modified ( TICS-M assess baseline cognitive function phone ) Brief Test Adult Cognition Telephone ( BTACT assess baseline cognitive function phone ) . All study subject randomly assign one 2 group prior surgery . The treatment group receive Rivastigmine patch preoperatively cover tegaderm dress placebo group receive tegaderm dress . Both group assess twice daily 9am 4pm 72 hour postoperatively Confusion Assessment Method Intensive Care Unit ( CAM-ICU ) , Memorial Delirium Assessment Scale ( MDAS ) Mini Mental Status Examination ( diagnose delirium ass severity ) . At one month three month postoperatively subject postoperative MMSE 27 less assessed postoperative cognitive dysfunction . The assessment perform phone TICS-M Brief Test Adult Cognition Telephone . Outcomes divide Primary Secondary outcomes . Primary outcome determine proportion patient least one episode POD treatment placebo group , diagnose CAM-ICU . Secondary outcome determine proportion patient development POCD group , diagnose TICS-M 1 month postoperatively . Secondary outcome also determine cumulative number POD episode within first 3 day hospital stay diagnose CAM-ICU , severity POD diagnose MDAS , recovery cognitive function diagnose MMSE , TICS-M BTACT , length hospital stay .</detailed_description>
	<mesh_term>Delirium</mesh_term>
	<mesh_term>Cognition Disorders</mesh_term>
	<mesh_term>Rivastigmine</mesh_term>
	<criteria>65 â‰¥ y.o . undergoing major elective surgery 2 hour length one following : Preoperative cognitive impairment Age &gt; 70 y.o . Use psychoactive medication History prior delirium Severe illness/comorbidity Delirium admission Profound dementia No spoken/written English An emergent procedure Hypersensitivity Rivastigmine</criteria>
	<gender>All</gender>
	<minimum_age>65 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>Postoperative Delirium</keyword>
	<keyword>Postoperative Cognitive Dysfunction</keyword>
	<keyword>Rivastigmine</keyword>
	<keyword>Exelon</keyword>
	<keyword>Memory impairment</keyword>
	<keyword>Delirium</keyword>
	<keyword>Cognitive function</keyword>
</DOC>